98 related articles for article (PubMed ID: 12428904)
1. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
Gupta B; Torchilin VP
Cancer Immunol Immunother; 2007 Aug; 56(8):1215-23. PubMed ID: 17219149
[TBL] [Abstract][Full Text] [Related]
2. Introduction to the supplement, "Cancer Therapy with Antibodies and Immunoconjugates".
Goldenberg DM
Cancer; 2010 Feb; 116(4 Suppl):1011-2. PubMed ID: 20127946
[TBL] [Abstract][Full Text] [Related]
3. Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.
Cazzamalli S; Corso AD; Neri D
Chimia (Aarau); 2017 Oct; 71(10):712-715. PubMed ID: 29070415
[TBL] [Abstract][Full Text] [Related]
4. Emerging Evidence on
Petronio Petronio G; Pietrangelo L; Cutuli MA; Magnifico I; Venditti N; Guarnieri A; Abate GA; Yewhalaw D; Davinelli S; Di Marco R
Microorganisms; 2022 Oct; 10(10):. PubMed ID: 36296259
[TBL] [Abstract][Full Text] [Related]
5. How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.
Garofalo M; Grazioso G; Cavalli A; Sgrignani J
Molecules; 2020 Apr; 25(7):. PubMed ID: 32290224
[TBL] [Abstract][Full Text] [Related]
6. Lipid-based drug carriers for prodrugs to enhance drug delivery.
Zaro JL
AAPS J; 2015 Jan; 17(1):83-92. PubMed ID: 25269430
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death.
Robinson MW; Overmeyer JH; Young AM; Erhardt PW; Maltese WA
J Med Chem; 2012 Mar; 55(5):1940-56. PubMed ID: 22335538
[TBL] [Abstract][Full Text] [Related]
8. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems.
Sharma A; Madhunapantula SV; Robertson GP
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):47-69. PubMed ID: 22097965
[TBL] [Abstract][Full Text] [Related]
9. The multiple faces of self-assembled lipidic systems.
Tresset G
PMC Biophys; 2009 Apr; 2(1):3. PubMed ID: 19374753
[TBL] [Abstract][Full Text] [Related]
10. Nanovehicular intracellular delivery systems.
Prokop A; Davidson JM
J Pharm Sci; 2008 Sep; 97(9):3518-90. PubMed ID: 18200527
[TBL] [Abstract][Full Text] [Related]
11. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody.
Meissner JM; Toporkiewicz M; Czogalla A; Matusewicz L; Kuliczkowski K; Sikorski AF
J Control Release; 2015 Dec; 220(Pt A):515-528. PubMed ID: 26585505
[TBL] [Abstract][Full Text] [Related]
12. New solid tumor targets for therapeutic monoclonal antibodies.
Papkoff J
Expert Opin Ther Targets; 2007 May; 11(5):585-8. PubMed ID: 17465718
[TBL] [Abstract][Full Text] [Related]
13. Improving the efficacy of antibody-based cancer therapies.
Carter P
Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
[TBL] [Abstract][Full Text] [Related]
14. Tumor-directed targeting of liposomes.
Park YS
Biosci Rep; 2002 Apr; 22(2):267-81. PubMed ID: 12428904
[TBL] [Abstract][Full Text] [Related]
15. Ligand-targeted liposomal anticancer drugs.
Sapra P; Allen TM
Prog Lipid Res; 2003 Sep; 42(5):439-62. PubMed ID: 12814645
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
